MYC overexpression
|
Diffuse Large B Cell Lymphoma
|
MYC overexpression
|
Diffuse Large B Cell Lymphoma
|
tisagenlecleucel-T Resistant: C3 – Early Trials
|
tisagenlecleucel-T Resistant: C3 – Early Trials
|
MYC overexpression
|
Mediastinal B Cell Lymphoma
|
MYC overexpression
|
Mediastinal B Cell Lymphoma
|
lisocabtagene maraleucel Resistant: C3 – Early Trials
|
lisocabtagene maraleucel Resistant: C3 – Early Trials
|
MYC overexpression
|
Diffuse Large B Cell Lymphoma
|
MYC overexpression
|
Diffuse Large B Cell Lymphoma
|
azacitidine oral Sensitive: C3 – Early Trials
|
azacitidine oral Sensitive: C3 – Early Trials
|
MYC overexpression
|
Cervical Cancer
|
MYC overexpression
|
Cervical Cancer
|
GS-626510 Sensitive: D – Preclinical
|
GS-626510 Sensitive: D – Preclinical
|
MYC overexpression
|
Mantle Cell Lymphoma
|
MYC overexpression
|
Mantle Cell Lymphoma
|
TG-1701 Sensitive: D – Preclinical
|
TG-1701 Sensitive: D – Preclinical
|
MYC overexpression
|
Multiple Myeloma
|
MYC overexpression
|
Multiple Myeloma
|
bortezomib Resistant: D – Preclinical
|
bortezomib Resistant: D – Preclinical
|
MYC overexpression
|
Thyroid Gland Carcinoma
|
MYC overexpression
|
Thyroid Gland Carcinoma
|
MLN8237 Sensitive: D – Preclinical
|
MLN8237 Sensitive: D – Preclinical
|
MYC overexpression
|
Diffuse Large B Cell Lymphoma
|
MYC overexpression
|
Diffuse Large B Cell Lymphoma
|
INCB57643 Sensitive: D – Preclinical
|
INCB57643 Sensitive: D – Preclinical
|
MYC overexpression
|
Mantle Cell Lymphoma
|
MYC overexpression
|
Mantle Cell Lymphoma
|
venetoclax Sensitive: D – Preclinical
|
venetoclax Sensitive: D – Preclinical
|
MYC overexpression
|
Gastric Cancer
|
MYC overexpression
|
Gastric Cancer
|
WB100 Sensitive: D – Preclinical
|
WB100 Sensitive: D – Preclinical
|
MYC overexpression
|
Pancreatic Ductal Adenocarcinoma
|
MYC overexpression
|
Pancreatic Ductal Adenocarcinoma
|
WB100 Sensitive: D – Preclinical
|
WB100 Sensitive: D – Preclinical
|
MYC overexpression
|
AML
|
MYC overexpression
|
AML
|
WB100 Sensitive: D – Preclinical
|
WB100 Sensitive: D – Preclinical
|
MYC overexpression
|
NSCLC
|
MYC overexpression
|
NSCLC
|
MRT-2359 Sensitive: D – Preclinical
|
MRT-2359 Sensitive: D – Preclinical
|
MYC overexpression
|
NSCLC
|
MYC overexpression
|
NSCLC
|
ROS1 inhibitor Resistant: D – Preclinical
|
ROS1 inhibitor Resistant: D – Preclinical
|
MYC overexpression
|
Lymphoma
|
MYC overexpression
|
Lymphoma
|
brusatol Sensitive: D – Preclinical
|
brusatol Sensitive: D – Preclinical
|